# DESTINY Breast Respond HER2-low Europe

> **NCT05945732** · — · RECRUITING · sponsor: **Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company** · enrollment: 1155 (estimated)

## Conditions studied

- Unresectable Breast Cancer
- Metastatic Breast Cancer
- HER2-low Expressing Breast Cancer

## Interventions

- **DRUG:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT05945732
- **Lead sponsor:** Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-24
- **Primary completion:** 2028-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 1155 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05945732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05945732, "DESTINY Breast Respond HER2-low Europe". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05945732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*